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1 |  INTRODUCTION
Severe acute respiratory syndrome coronavirus- 2 (SARS- 
CoV- 2) infection, first reported in Wuhan, China, in 
December 2019, is spreading rapidly around the world. The 
site primarily affected by this infection is the respiratory 
system; however, simultaneous or even isolated cardiac in-
volvement has been observed in some cases.1 Coronavirus 
disease 2019 (COVID- 19) can be diagnosed both via reverse 
transcription- polymerase chain reaction (RT- PCR) using 
pharyngeal swab specimens and via high- resolution com-
puted tomography (CT) scans of the chest according to the 
recently published guidelines.2
Some investigations have furnished robust evidence of 
myocardial injury during the active course of COVID- 19,3,4 
with 8% of this group of patients suffering an acute myocar-
dial insult.5 It is such high risks of virus- induced myocardial 
damage that render cardiac magnetic resonance (CMR) im-
aging helpful for the care of cases with suspected or con-
firmed COVID- 19. CMR is an excellent tool for functional 
and morphological studies in that it confers reliable tissue 
characterization and differentiation between acute ischemic 
and nonischemic myocardial injuries.6
Late gadolinium enhancement (LGE) sequences are 
used for the detection of myocardial necrosis and fibro-
sis and are deemed to be of prognostic value in determin-
ing the increased risk of adverse cardiovascular events.7A 
greater extent of fibrosis, according to LGE, is associated 
with a higher risk of potentially life- threatening ventricular 
arrhythmias.8
We herein present the CMR portrait of 2 definite cases of 
COVID- 19 with evidence of extensive myocardial fibrosis.
2 |  CASE 1
A 39- year- old woman presented to the emergency depart-
ment with dyspnea of 1- month duration. The patient was a 
known case of asthma. On admission, she had a body tem-
perature of 38°C, a blood pressure of 120/80 mm Hg, and 
a heart rate of 124 bpm. Physical examination revealed de-
creased breath sounds at lung bases with rhonchi. Her oxygen 
saturation level in ambient air was estimated at 89%. Given 
the coronavirus outbreak, nasopharyngeal and oropharyngeal 
swabs were immediately obtained, which indicated SARS- 
CoV- 2 positivity.
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A subgroup of COVID- 19 patients with cardiac magnetic resonance imaging evi-
dence of myocardial inflammation may exhibit subendocardial fibrosis, compatible 
with myocardial infarction, while epicardial coronary arteries are normal.
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Panel electrocardiography (ECG) showed sinus tachy-
cardia with nonspecific ST- T wave changes (Figure  1A). 
Additionally, the level of high- sensitivity troponin I (hs- TnI) 
was elevated (0.54 µg/L; cut point <0.03 µg/L). Transthoracic 
echocardiography demonstrated severe left ventricular (LV) 
systolic dysfunction (ejection fraction  =  30%), associated 
with akinesia at the mid- to- apical portions of the anteroseptal 
and inferoseptal regions and hypokinesia in the other LV seg-
ments. There was no evidence of ventricular dilation and val-
vular abnormality. Also, we observed a mobile clot attached 
to the inferoapical LV portion, together with mild pericardial 
effusion (Figure 1B and C). Chest CT depicted severe mul-
tifocal consolidation and ground- glass opacity in both lungs 
(Figure 1D).
In the primary center, anticoagulation therapy (enoxapa-
rin 60 mg BID, followed by apixaban 5 mg BID at discharge) 
and heart failure treatment (captopril 25 mg BID and spirono-
lactone 25 mg QD, followed by carvedilol 3.25 mg BID after 
lung congestion reduction at discharge) were administered. 
Lopinavir/ritonavir was prescribed for COVID- 19 treatment 
under the supervision of an infectious disease specialist. 
Electrolytes were monitored during the admission and peri-
odically after discharge.
Two months after discharge from the primary center, 
the patient was referred to our tertiary referral center for 
cardiac evaluation. CMR revealed myocardial edema, pre-
dominantly in the septal wall, and hyperemia (evidenced 
by early gadolinium enhancement sequences). Extensive 
patchy myocardial fibrosis with subepicardial, midwall, 
and subendocardial involvement in different LV segments 
(not in a specific vascular territory) was depicted on LGE 
sequences (Figure  2A- D). Pulmonary CT after 2  months 
showed substantial resolution in opacities despite nota-
ble cardiac involvement (Figure  1E). Also, computed to-
mography angiography (CTA) was performed to rule out 
coronary artery disease (CAD), which showed normal epi-
cardial coronary arteries (Figure 2E- G).
Therefore, a diagnosis of active myocarditis due to SARS- 
CoV- 2 infection with a unique involvement pattern was es-
tablished. Given the patient's challenging condition, she was 
referred to a heart failure specialist for heart failure treatment, 
to be followed by another CMR 1 month later.
F I G U R E  1  Electrocardiography, echocardiography, and chest computed tomography of CASE 1 are illustrated herein. A, Electrocardiography 
reveals sinus tachycardia with nonspecific ST- T wave changes. B, C, Transthoracic echocardiography shows a large mobile clot attached to the 
inferoapical left ventricular portion (arrow), together with mild pericardial effusion (arrowhead). D, E, Unenhanced chest computed tomography 
scan of the patient at initial coronavirus manifestations (D) and after 2 months (E) is depicted. Images are in the parenchymal window and 
from the maximum involvement level of the lung fields. D, Confluent mixed ground- glass opacity and consolidation areas in both central and 
peripheral distributions, associated with focal vascular dilatation; additionally, pleural and pericardial effusions are noted. E, There are a few faintly 
hyperdense residual opacities more in a nodular pattern with the adjacent linear densities, representing a fibrotic reaction
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3 |  CASE 2
The patient was a 31- year- old man, who had a history of 
 bicuspid aortic valve with severe aortic valve insufficiency, 
preserved cardiac function (ejection fraction  =  50%- 55%), 
and severe LV enlargement in the preceding year. He had 
refused to undergo valve replacement surgery.
On presentation to our center, the patient had dys-
pnea, atypical chest pain, a low- grade fever, and coughs. 
Additionally, he had a body temperature of 38°C, a blood 
pressure of 135/55  mm  Hg, and a heart rate of 95  bpm. 
Physical examination was unremarkable, except for basal 
lung rales and 3/6 diastolic murmurs in the second inter-
costal space. ECG illustrated evidence of LV hypertrophy 
(Figure 3A).
Laboratory evaluation revealed an elevated hs- TnI level 
(0.32 µg/L), combined with a lymphocyte count of 1100/µL. 
Additionally, RT- PCR through pharyngeal swab specimens 
was positive.
Transthoracic echocardiography showed severe LV sys-
tolic dysfunction (ejection fraction = 10%- 15%) and enlarge-
ment, severe hypokinesia in all LV segments with preserved 
tissue, a bicuspid aortic valve (fusion of the left and right 
coronary cusps) with subsequent severe aortic valve insuffi-
ciency, holodiastolic flow reversal in the descending thoracic 
aorta and the abdominal aorta, and a dilated ascending aorta 
(Figure 3B- E). In comparison with the previous echocardiog-
raphy report, documented a year earlier, a meaningful decline 
in the ejection fraction without a notable change in LV vol-
ume was recorded.
Chest CT depicted peripheral pulmonary ground- glass 
opacity and consolidation (Figure 4A). CMR was carried out 
for precise evaluation of the cause of the ventricular dysfunc-
tion. Similar to CASE 1, there was evidence of myocardial 
edema, and hyperemia along with extensive myocardial fibro-
sis in the subepicardial, midwall, and subendocardial regions 
(Figure 4B- D). CTA was performed to rule out CAD, which 
revealed normal epicardial coronary arteries (Figure 5).
4 |  DISCUSSION
COVID- 19– induced myocardial injury, with myocardial 
edema and fibrosis, is associated with adverse cardiac out-
comes.3 Therefore, appropriate treatment crucially requires a 
prompt diagnosis in the early stages of the infection.
In COVID- 19 cases with new- onset heart failure with-
out known cardiovascular disease risk factors, myocarditis 
should be considered. Endomyocardial biopsy is not advis-
able in COVID- 19 patients with associated myocarditis.4 The 
F I G U R E  2  Cardiac magnetic resonance and coronary computed tomography angiography images of CASE 1 are illustrated herein. A, Short 
tau inversion recovery sequence in the midventricular short- axis view shows evidence of myocardial edema. B- D, Short- axis (B) 3- chamber (C) 
and 4- chamber (D) views depict evidence of patchy subepicardial, midwall, and subendocardial to transmural late gadolinium enhancement, 
representative of myocardial fibrosis. E- G, Curved multiplanar reconstruction images of normal left anterior descending (between lines in E), 
diagonal branch (between lines in F), and right (between lines in G) coronary arteries are depicted herein
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CMR diagnosis of myocarditis (Lake Louise criteria) is on 
the basis of the presence of myocardial edema, hyperemia, 
and replacement fibrosis, with the latter evidenced by patchy 
LGE in affected regions. The most common locations of fi-
brosis are subepicardial and midmyocardial layers.9
In this report, we interpreted the CMR findings of 2 
definite cases of COVID- 19 with cardiac involvement. 
They both exhibited myocardial edema and hyperemia, 
representing underlying inflammation. In CASE 1, the 
myocardial edema persisted for 2 months; accordingly, we 
believe that cardiac involvement in SARS- CoV- 2 infec-
tion can progress to a type of chronic active myocarditis or 
some degree of persistent myocardial edema. In a remark-
able study by Puntmann et al,10 a cohort of 100 patients 
underwent follow- up CMR 79  days after recovery from 
SARS- CoV- 2 infection, and cardiac involvement and active 
myocardial edema were scintillatingly detected in 78% and 
60%, respectively, independent of preexisting conditions 
and the disease course. A salient finding in our patients 
was the concurrent involvement of all 3 myocardial lay-
ers, particularly the subendocardial stripe in the different 
LV segments. Subendocardial fibrosis in a specific vascu-
lar territory is a discriminating feature for differentiating 
acute myocarditis from myocardial infarction in that when 
present, it makes CAD the most probable of all differen-
tial diagnoses. Nonetheless, in both of our cases, CAD was 
ruled out by CTA. According to the published investiga-
tions, COVID- 19– induced myocardial injury is a result of 
a combination of causes.11
The presence of myocardial edema and typical subepi-
cardial/midmyocardial fibrosis in our patients may be in line 
with described inflammatory cascades in the COVID- 19 con-
text. The existence of subendocardial fibrosis is attributable 
to probable microvascular damage caused by COVID- 19. 
We, thus, postulate that a combination of cytokine storms, 
inflammatory changes, and microvascular damage was cul-
pable for ischemia with consequent acute myocardial injury 
in our cases.
On the other hand, in CASE 1, the presence of an LV 
clot in the acute phase of the disease indicated the inherent 
risk of clot formation, which might be due to inflammatory 
changes. Indeed, we may assume that LV clots can cause 
coronary artery embolism and the resultant myocardial 
infarction.12
In a case report, Gravinay et al13 described a patient with 
respiratory symptoms in favor of COVID- 19. Despite the 
negative RT- PCR and chest CT results, CMR, conducted 
8 days after presentation, showed subepicardial inferolateral 
F I G U R E  3  Electrocardiography, echocardiography, and chest computed tomography of CASE 2 A are illustrated herein. Electrocardiography 
reveals evidence of left ventricular hypertrophy. B- E, Transthoracic echocardiography in the apical 4- chamber view (B) shows severe left 
ventricular dilation, continuous- wave Doppler imaging (C) reveals the diastolic jet of aortic regurgitation, and pulsed- wave recording and color M- 
mode recording (D, E) indicate holodiastolic flow reversal within the abdominal aorta and the descending thoracic aorta, respectively (arrow)
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LV wall edema, patchy LGE, and an LV apical clot in the 
presence of a normal LV function. These findings are com-
patible with active myocarditis. Ultimately, serological tests, 
including immunoglobulin G and immunoglobulin M, for 
SARS- CoV- 2 immunization, were positive. Gravinay and 
colleagues, thus, underscored the crucial role of CMR in the 
diagnostic workup of cases with suspected COVID- 19.
With respect to CASE 2, we believe that the severe de-
cline in LV systolic function in the absence of a significant 
rise in LV volume could not have been due to the rapid pro-
gression of valve insufficiency. The patient had no disorders 
such as aortic valve endocarditis that would have caused a 
sudden deterioration in LV systolic function. Moreover, cor-
onary CTA, which is the preferred method to rule out CAD 
based on the suggested guidelines, showed no abnormality.4 
We suspect that the diminished ejection fraction in CASE 2 
may have been in consequence of an acute process such as 
myocarditis induced by SARS- CoV- 2. This notion chimes in 
with the findings of some studies concluding that heart fail-
ure could follow myocarditis in the context of SARS- CoV- 2 
infection.11,12
5 |  CONCLUSIONS
SARS- CoV- 2 can influence the heart through different 
pathophysiologic mechanisms. An unusual pattern of sub-
endocardial fibrosis, typical for myocardial infarction, is 
recognizable in the CMR of these patients in the absence of 
CAD. Multimodality CMR studies may have a crucial role 
F I G U R E  4  Cardiac magnetic resonance and chest computed 
tomography findings of CASE 2 are presented herein. A, Coronal 
unenhanced pulmonary computed tomography reveals segmental 
peripheral ground- glass opacities, which are highly suggestive 
of COVID- 19– related pneumonia. B, Evidence of COVID- 19 
myocarditis is depicted in the late gadolinium enhancement sequence 
in the midventricular short- axis view. C, Short tau inversion recovery 
sequence in the midventricular short- axis view shows myocardial 
edema. D, Two- chamber view late gadolinium enhancement sequence 
demonstrates patchy myocardial fibrosis in the subepicardial and 
midwall regions
F I G U R E  5  Coronary computed tomography angiography of CASE 2 is demonstrated. A- D, Curved multiplanar reconstruction images of 
normal left anterior descending (between lines in A), left circumflex (between lines in B), a well- developed obtuse marginal branch (between lines 
in C), and right (between lines in D) coronary arteries are shown
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in the diagnosis of the different pathophysiologic aspects of 
COVID- 19.
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